8 research outputs found

    Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018)

    Get PDF
    Objective: To analyse the susceptibility to ceftolozane-tazobactam and comparators in Enterobacterales and Pseudomonas aeruginosa isolates recovered from intraabdominal (IAI), urinary (UTI), respiratory (RTI) and bloodstream infection (BSI) in the SMART (Study for Monitoring Antimicrobial Resistance Trends) study. Methods: The susceptibility of 5,351 isolates collected in 11 Spanish hospitals (2016-2018) were analysed (EUCAST-2020 criteria) by broth microdilution and were phenotypically studied for the presence of extended-spectrum beta-lactamases (ESBL). Ceftolozane-tazobactam and/or carbapenem resistant isolates were genetically characterized for ESBL and carbapenemases. Results: Escherichia coli was the most frequent pathogen (49.3% IAI, 54.9% UTI, 16.7% RTI and 50% BSI), followed by Klebsiella pneumoniae (11.9%, 19.1%, 13.1% and 15.4%, respectively). P. aeruginosa was isolated in 9.3%, 5.6%, 32% and 9%, respectively. The frequency of isolates with ESBLs (2016-2017) was: 30.5% K. pneumoniae, 8.6% E. coli, 2.3% Klebsiella oxytoca and 0.7% Proteus mirabilis. Ceftolozane-tazobactam was very active against non-ESBL-(99.3% susceptible) and ESBL-(95.2%) producing E. coli being less active against K. pneumoniae (98% and 43.1%, respectively) isolates. CTX-M-15 was the most prevalent ESBL in E. coli (27.5%) and K. pneumoniae (51.9%) frequently associated with OXA-48-like carbapenemase. Overall, 93% of P. aeruginosa isolates were susceptible to ceftolozane-tazobactam, preserving this activity (>75%) in isolates resistant to other beta-lactams except in those resistant to meropenen or ceftazidime-avibactam. GES-5, PER-1, VIM-1/2 were the most prevalent enzymes in isolates resistant to ceftolozane-tazobactam. Conclusions: Ceftolozane-tazobactam showed high activity rates against isolates recovered in the SMART study although it was affected in K. pneumoniae and P. aeruginosa isolates with ESBL and/or carbapenemases

    Activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020

    Get PDF
    Objectives. To determine susceptibility to the novel β-lactam/β-lactamase inhibitor combination imipenem/relebactam in clinical isolates recovered from intra-abdominal (IAI), urinary (UTI), respiratory (RTI) and bloodstream (BSI) infections in the SMART (Study for Monitoring Antimicrobial Resistance Trends) study in SPAIN during 2016 – 2020. Methods. Broth microdilution MICs for imipenem/relebactam and comparators were determined by a central laboratory against isolates of Enterobacterales and Pseudomonas aeruginosa. MICs were interpreted using EUCAST-2021 breakpoints. Results. In total, 5,210 Enterobacterales and 1,418 P. aeruginosa clinical isolates were analyzed. Imipenem/relebactam inhibited 98.8% of Enterobacterales. Distinguishing by source of infection susceptibility was 99.1% in BSI, 99.2% in IAI, 97.9% in RTI, and 99.2% in UTI. Of intensive care unit isolates (ICU) 97.4% were susceptible and of non-ICU isolates 99.2% were susceptible. In Enterobacterales, activity against Class A, Class B and Class D carbapenemases was 96.2%, 15.4% and 73.2%, respectively. In P. aeruginosa, imipenem/relebactam was active in 92.2% of isolates. By source of infection it was 94.8% in BSI, 92.9% in IAI, 91.7% in RTI, and 93.1% in UTI. An 88.7% of ICU isolates and 93.6% of non-ICU isolates were susceptible to imipenem/relebactam. Imipenem/relebactam remained active against P. aeruginosa ceftazidime-resistant (76.3%), cefepime-resistant (73.6%), imipenem-resistant (71.5%) and piperacillin-resistant (78.7%) isolates. Of all multidrug-resistant or difficult-to-treat resistance P. aeruginosa isolates, 75.1% and 46.2%, respectively, were susceptible to imipenem/relebactam. Conclusions. Imipenem/relebactam showed high rates of susceptibility in Enterobacterales and P. aeruginosa isolates from different sources of infection as well as depending on patients’ location (ICU or non-ICU scenarios)

    Variante Ómicron (BA.1) presenta menor replicación in vitro que la variante del año 2020 (B.1.1) del virus SARS-CoV-2

    Get PDF
    Sr. Editor, A dos años de la pandemia de la COVID-19, a finales de junio del 2022 los peruanos estamos enfrentando la cuarta ola causada por la variante Ómicron del virus SARS-CoV-2 (Severe acute respiratory syndrome coronavirus). A diferencia de la primera ola de la COVID-19 en marzo del 2020, causada por el linaje viral B.1.1, la tercera y cuarta ola han sido causadas por los linajes y sublinajes de la variante Ómicron (1,2), los cuales se caracterizan por ser más transmisibles, pero causan la enfermedad menos grave y menor mortalidad, comportamiento observado durante la evolución epidemiológica de la enfermedad. Con el objetivo de evaluar el comportamiento in vitro en la replicación viral del linaje B.1.1, linaje de mayor frecuencia y persistencia en el tiempo durante la primera ola del 2020 (3), con el linaje BA.1 (variante Ómicron) de la tercera ola en el Perú, se comparó la replicación de 10 generaciones sucesivas de las 2 variantes (B.1.1 y BA.1), observándose que el linaje del 2020 se replica rápidamente in vitro, con alto título viral y causando daño celular, a diferencia de la variante Ómicron (linaje BA.1) que presenta replicación lenta causando leve daño celular. Este hallazgo podría correlacionar con la gravedad de la enfermedad observada en las olas ocasionadas por las mencionadas variantes, y contrasta con la capacidad de infección observada por las mismas, aunque otro factor que juega un rol importante es la protección inmune, sea por infecciones previas a lo que se suma la vacunación de la población

    Starkeya nomas sp. nov., a prosthecate and budding bacterium isolated from an immunocompromized patient

    Get PDF
    Strain HF14-78462T is an environmental bacterium found in clinical samples from an immunocompromized patient in 2014 at Hospital Universitari i Politècnic La Fe (Valencia, Spain). Phenotypically, strain HF14-78462T cells were Gram-stain-negative, aerobic, non-spore forming and non-motile small rods which formed mucous and whitish-translucent colonies when incubated at 20-36 °C. Phylogenetic analyses based on the 16S rRNA genes and the whole genomes of closest sequenced relatives confirmed that strain HF14-78462T is affiliated with the genus Starkeya. The strain was oxidase, catalase and urease positive; but indole, lysine decarboxylase, ornithine decarboxylase and DNase negative, did not produce H2S and was able to utilize a wide variety of carbon sources including acetamide, adonitol, amygdalin, l-arabinose, citric acid, glucose, mannitol and melibiose. Unlike Starkeya novella and Starkeya koreensis, strain HF14-78462T failed to grow in thiosulphate-oxidizing media and had a narrower temperature growth range. Its genome was characterized by a size of 4.83 Mbp and a C+G content of 67.75 mol%. Major fatty acids were C18:1 ω7c, cyclo C19 : 0 and C16 : 0, its polar acids were diphosphatidylglycerol, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol and an aminophospholipid; while the ubiquinones were Q9 (1.8 %) and Q10 (98.2 %). Digital DNA-DNA hybridization values were 41 and 41.4 against S. novella and S. koreensis, respectively, while average nucleotide identity values were around 84 %. Phenotypic, average nucleotide identity and phylogenomic comparative studies suggest that strain HF14-78462T is a new representative of the genus Starkeya and the name Starkeya nomas sp. nov. is proposed. The type strain is HF14-78462T (=CECT 30124T=LMG 31874T).Financial support was obtained by the IIS project 2013/0437.S

    A navegar con Cristóbal Colón

    Full text link
    Se desarrolla un proyecto de innovación educativa en torno a la figura de Cristóbal Colón, cobrando importancia también otros hechos derivados de sus descubrimiento, como es el caso del conocimiento de otras culturas, sus costumbres y tradiciones. En el momento histórico del V centenario de de la muerte de Cristóbal Colón, toda la comunidad educativa se embarca y participa en la experiencia innovadora que promueve el interés por la lectura, fomenta la coordinación del profesorado, la convivencia y la socialización del profesorado. El proyecto pretende entre otros objetivos: conocer el personaje de Cristóbal Colón y su importancia en la historia, reconociendo la repercusión que tuvo el Descubrimiento de América y los Reyes Católicos; fomentar la convivencia en el centro a través de las diferentes actividades del proyecto, educando en valores y en el respeto a la pluralidad; acercar al alumnado al oficio de marinero a través de las diferentes experiencias y actividades. Las sesiones de trabajo se han desarrollado combinando la formación teórica a través de las exposiciones de ponentes externos, las reflexiones de grupo y momentos de debate donde el intercambio de experiencias ha sido positivo y valorado por los asistentes, y el desarrollo práctico de las sesiones han sido ejecutadas por cada tutor o especialista en el aula con el alumnado, teniendo en cuenta cada contexto y nivel educativo.Castilla y LeónConsejería de Educación. Dirección General de Universidades e Investigación; Monasterio de Nuestra Señora de Prado, Autovía Puente Colgante s. n.; 47071 Valladolid; +34983411881; +34983411939ES

    Long-term effect of a practice-based intervention (HAPPY AUDIT) aimed at reducing antibiotic prescribing in patients with respiratory tract infections

    Full text link
    corecore